15 results
8-K
EX-99.1
UBX
Unity Biotechnology Inc
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
UBX1325 had a favorable safety and tolerability profile with no evidence of intraocular inflammation
UNITY to host investor call with retinal expert
Robert
8-K
EX-99.1
UBX
Unity Biotechnology Inc
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
was 59.4% at 6 months after a single injection, as compared to only 37.5% in the sham-treated arm
UNITY to host investor call with retinal expert Arshad M
8-K
EX-99.1
yx0j ltpfp8
12 Aug 22
UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:18am
PRE 14A
kaakjwmt bg
12 Apr 22
Preliminary proxy
4:02pm
8-K
EX-10.1
7vbdbbjjpu4j8yzs11h
15 Dec 21
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-10.1
f04aetl1z2q2u29
4 Aug 20
Unity Biotechnology Announces $80M Debt Financing from Hercules Capital
4:15pm
DEF 14A
3moo78d
26 Apr 19
Definitive proxy
5:27pm
10-K
EX-10.23
lxt658 b9fw0rqy
6 Mar 19
Annual report
8:06am
424B4
orbnk6sr
4 May 18
Prospectus supplement with pricing info
12:00am
- Prev
- 1
- Next